TransMedics Group (NASDAQ:TMDX) PT Raised to $169.00

TransMedics Group (NASDAQ:TMDX) had its price objective boosted by equities research analysts at Canaccord Genuity Group from $117.00 to $169.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 6.65% from the company’s current price.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald started coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Oppenheimer increased their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday. JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Piper Sandler increased their target price on TransMedics Group from $120.00 to $170.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $162.25.

TransMedics Group Stock Performance

Shares of TMDX stock traded up $16.20 during trading on Thursday, hitting $158.46. The company’s stock had a trading volume of 1,365,655 shares, compared to its average volume of 745,199. The company has a market cap of $5.22 billion, a PE ratio of -466.12 and a beta of 1.98. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The business has a fifty day moving average of $143.54 and a 200-day moving average of $110.29. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $171.98.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period in the prior year, the company posted ($0.03) earnings per share. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. As a group, research analysts anticipate that TransMedics Group will post 0.81 earnings per share for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 30,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 30,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $130.07, for a total value of $3,902,100.00. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,017,905.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,744,059.55. The disclosure for this sale can be found here. Over the last three months, insiders have sold 113,367 shares of company stock valued at $15,145,741. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter worth $241,000. Commonwealth Equity Services LLC increased its stake in shares of TransMedics Group by 62.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 6,497 shares of the company’s stock worth $979,000 after purchasing an additional 2,491 shares in the last quarter. Matisse Capital bought a new position in TransMedics Group in the 2nd quarter worth $452,000. International Assets Investment Management LLC bought a new position in TransMedics Group in the 2nd quarter worth $47,000. Finally, Signaturefd LLC boosted its holdings in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.